Document is current
Any future updates will be listed below
-
Authors
Lee, Pei-Chang
Li, Po-Yu
Lee, Cheng-Yun
Lin, Shian-Ren
Wu, Chi-Jung
Hung, Ya-Wen
Chen, Yu-Hua
Chan, Jun-Wen
Mon, Hsien-Chen
Lee, Chieh-Ju
Chi, Chen-Ta
Lee, I-Cheng
Hou, Ming-Chih
Chao, Yee
Huang, Yi-Hsiang
Lee, Jan-Mou
-
Funding
Funding for this research was provided by:
Yin Shu-Tien Foundation Taipei Veterans General Hospital-National Yang Ming Chiao Tung University Excellent Physician Scientists Cultivation Program (113-V-A-007)
National Science and Technology Council (MOST 108-2321-B-010 -017, MOST 109-2314-B-010-034-MY3, NSTC 112-2314-B-A49-032-MY3, NSTC 113-2314-B-075-054-MY3)
Taipei Veterans General Hospital (V108B-038, V109C-048, V110B-031, V110C-144, V111C-107, V112B-040, V112C-070, V113C-103, V114C-127, VN111-02, VN112-11, VN113-11, VN114-10, VGHUST113-G1-9-1, and VGHUST113-G1-9-2)
- License Information
-
More Information
Article History
Received: 31 March 2025
Accepted: 26 August 2025
First Online: 24 October 2025
Declarations
:
: Designation of the study protocol complied the Declaration of Helsinki. The Institutional Review Board of Taipei Veterans General Hospital reviewed and approved the study protocol (approval numbers: 2017-09-007CC, 2019-07-007AC, and 2019-08-006B). All blood collection were performed after participants signing the informed consent form.
: Not applicable.
: PYL, CYL, SRL, YHC, JWC are employees of FullHope Biomedical Co., Ltd. JML is the chief executive officer of FullHope Biomedical Co., Ltd. YC is the board president of FullHope Biomedical Co., Ltd. This study is under patent filing by FullHope Biomedical Co., Ltd. YHH received research grants from Gilead Sciences and AstraZeneca, honoraria from AstraZeneca, Gilead Sciences, Eisai, and Roche, and had advisory role for AstraZeneca, Eisai, and Roche.
